drugset / Trial / NCT00456924

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

NCT00456924

Phase 2 Completed 48 enrolled HRA Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.

Timeline

Start
2004-01
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown 2.5 mg
Subject Ulipristal Acetate Unknown 5 mg
Subject Ulipristal Acetate Unknown 10 mg